A comprehensive view of Versanis Bio. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Eli Lilly successfully finalizes acquisition of Versanis Bio, expanding its portfolio to include bimagrumab, a drug in phase 2b study for overweight and obese adults, with potential payments to Versanis shareholders of up to US$1.925B
Published: August 17, 2023 by Eli Lilly & Co.
Eli Lilly extends US$2.4B tender offer for Dice Therapeutics acquisition to August 8; Lilly also announces agreement to buy clinical-stage biopharmaceutical firm Versanis Bio for US$1.92B
Published: July 26, 2023 by MarketLine
Eli Lilly to acquire drug developer Versanis for up to US$1.93B to boost its obesity drugs portfolio; Versanis's lead drug bimagrumab showing promising results in mid-stage trials
Published: July 14, 2023 by Proactive Investors

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count